Načítá se...
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
BACKGROUND: Patients with advanced squamous-cell non–small-cell lung cancer (NSCLC) who have disease progression during or after first-line chemotherapy have limited treatment options. This randomized, open-label, international, phase 3 study evaluated the efficacy and safety of nivolumab, a fully h...
Uloženo v:
| Vydáno v: | N Engl J Med |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4681400/ https://ncbi.nlm.nih.gov/pubmed/26028407 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1504627 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|